Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

© 2019 ISPOR–The professional society for health economics and outcomes research Objective: To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand. Methods: A Markov model comprising 3 health states (progression-free survival, progres...

Full description

Saved in:
Bibliographic Details
Main Authors: Unchalee Permsuwan, Sumitra Thongprasert, Buntitabhon Sirichanchuen
Format: Journal
Published: 2020
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073458329&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68362
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-68362
record_format dspace
spelling th-cmuir.6653943832-683622020-04-02T15:29:37Z Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand Unchalee Permsuwan Sumitra Thongprasert Buntitabhon Sirichanchuen Economics, Econometrics and Finance Medicine Pharmacology, Toxicology and Pharmaceutics © 2019 ISPOR–The professional society for health economics and outcomes research Objective: To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand. Methods: A Markov model comprising 3 health states (progression-free survival, progression, death) was used to estimate the long-term costs and health outcomes under a societal perspective with a lifetime horizon. Intervention was the combination of pemetrexed and cisplatin, AND the comparators were gemcitabine plus cisplatin and carboplatin plus paclitaxel. The efficacy and toxicity were obtained from landmark clinical trials, and the costs were based on a local Thai database. All costs and outcomes were discounted at 3%. The findings were reported as incremental cost-effectiveness ratios (ICERs) in both Thai baht (THB) and USD per quality-adjusted life year (QALY) gained. A series of sensitivity analyses, including 1-way and probabilistic sensitivity analyses, were performed. A cost-effectiveness acceptability curve was generated with a threshold of 160 000 THB/QALY or 4987 USD/QALY. Results: Under the base-case analysis, pemetrexed plus cisplatin had the greatest total cost among 3 regimens, yielding an ICER of 64 369.97 USD/QALY (2 064 989 THB/QALY) compared with gemcitabine plus cisplatin, and ICER of 8649.16 USD/QALY (277 465 THB/QALY) compared with carboplatin plus paclitaxel. The probabilistic sensitivity analysis results indicated that at the local Thai threshold, gemcitabine plus cisplatin was likely to be the most cost-effective regimen. Conclusions: At the current price of pemetrexed, the combination of pemetrexed plus cisplatin was not found to be a cost-effective first-line regimen for patients with non-small cell lung cancer at the local Thai threshold compared with the gemcitabine plus cisplatin and carboplatin plus paclitaxel regimens. 2020-04-02T15:25:35Z 2020-04-02T15:25:35Z 2020-05-01 Journal 22121102 22121099 2-s2.0-85073458329 10.1016/j.vhri.2019.04.005 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073458329&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/68362
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Economics, Econometrics and Finance
Medicine
Pharmacology, Toxicology and Pharmaceutics
spellingShingle Economics, Econometrics and Finance
Medicine
Pharmacology, Toxicology and Pharmaceutics
Unchalee Permsuwan
Sumitra Thongprasert
Buntitabhon Sirichanchuen
Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
description © 2019 ISPOR–The professional society for health economics and outcomes research Objective: To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand. Methods: A Markov model comprising 3 health states (progression-free survival, progression, death) was used to estimate the long-term costs and health outcomes under a societal perspective with a lifetime horizon. Intervention was the combination of pemetrexed and cisplatin, AND the comparators were gemcitabine plus cisplatin and carboplatin plus paclitaxel. The efficacy and toxicity were obtained from landmark clinical trials, and the costs were based on a local Thai database. All costs and outcomes were discounted at 3%. The findings were reported as incremental cost-effectiveness ratios (ICERs) in both Thai baht (THB) and USD per quality-adjusted life year (QALY) gained. A series of sensitivity analyses, including 1-way and probabilistic sensitivity analyses, were performed. A cost-effectiveness acceptability curve was generated with a threshold of 160 000 THB/QALY or 4987 USD/QALY. Results: Under the base-case analysis, pemetrexed plus cisplatin had the greatest total cost among 3 regimens, yielding an ICER of 64 369.97 USD/QALY (2 064 989 THB/QALY) compared with gemcitabine plus cisplatin, and ICER of 8649.16 USD/QALY (277 465 THB/QALY) compared with carboplatin plus paclitaxel. The probabilistic sensitivity analysis results indicated that at the local Thai threshold, gemcitabine plus cisplatin was likely to be the most cost-effective regimen. Conclusions: At the current price of pemetrexed, the combination of pemetrexed plus cisplatin was not found to be a cost-effective first-line regimen for patients with non-small cell lung cancer at the local Thai threshold compared with the gemcitabine plus cisplatin and carboplatin plus paclitaxel regimens.
format Journal
author Unchalee Permsuwan
Sumitra Thongprasert
Buntitabhon Sirichanchuen
author_facet Unchalee Permsuwan
Sumitra Thongprasert
Buntitabhon Sirichanchuen
author_sort Unchalee Permsuwan
title Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
title_short Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
title_full Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
title_fullStr Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
title_full_unstemmed Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
title_sort cost-utility analysis of first-line pemetrexed plus cisplatin in non-small cell lung cancer in thailand
publishDate 2020
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073458329&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68362
_version_ 1681426806385672192